Compare ALUR & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALUR | NVNO |
|---|---|---|
| Founded | 2009 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 7.3M |
| IPO Year | N/A | N/A |
| Metric | ALUR | NVNO |
|---|---|---|
| Price | $1.70 | $0.34 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.25 | N/A |
| AVG Volume (30 Days) | 77.4K | ★ 417.4K |
| Earning Date | 11-12-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,208,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.47 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $0.30 |
| 52 Week High | $16.81 | $5.62 |
| Indicator | ALUR | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 59.17 | 45.03 |
| Support Level | $1.18 | $0.35 |
| Resistance Level | $1.91 | $0.39 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 79.37 | 55.35 |
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.